A selective inhibitor of stearoyl-CoA desaturase
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PluriSln 1

Item No. 16161

Technical Information
Formal Name
2-phenylhydrazide-4-pyridinecarboxylic acid
CAS Number
91396-88-2
Synonyms
  • N’-phenyl-hydrazine-Isonicotinic acid
  • NSC 14613
Molecular Formula
C12H11N3O
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS(pH7.2) (1:1): 0.5 mg/mlEthanol: 20 mg/ml
λmax
235, 271 nm
SMILES
O=C(NNC1=CC=CC=C1)C2=CC=NC=C2
InChi Code
InChI=1S/C12H11N3O/c16-12(10-6-8-13-9-7-10)15-14-11-4-2-1-3-5-11/h1-9,14H,(H,15,16)
InChi Key
HUDWXDLBWRHCKO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    PluriSln 1 is an N-acyl phenylhydrazine derivative that inhibits stearoyl-CoA desaturase, a key enzyme for lipid metabolism that is expressed in human pluripotent stem cells (hPSCs).1 PluriSln 1 can selectively induce ER stress, attenuate protein synthesis, and induce apoptosis in hPSCs (EC50 = 2 µM) while sparing progenitor and differentiated cells.1 Because PluriSln 1 can selectively eliminate undifferentiated hPSCs, it was developed as a strategy to prevent tumorigenic risk from residual undifferentiated cells used during stem cell therapy. In immunocompromised mice, PluriSln 1 has been shown to effectively prevent teratoma formation from undifferentiated hPSCs.1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ben-David, U., Gan, Q.F., Golan-Lev, T., et alSelective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12(2), 167-179 (2013).